Geographic expansion Lucence is expanding offices across Asia and the United States, signaling growth in multiple markets and potential enterprise deals with regional healthcare providers, hospitals, and diagnostics labs.

Clinical collaboration Strategic partnerships with Mayo Clinic, NCCS, DxD Hub, and Brain Tumour Society Singapore indicate a pathway for co-developed diagnostics, clinical validation studies, and large-scale trials that can fuel joint sales opportunities.

AI driven profiling Investment in clinical-grade cancer profiling tests and AI-enabled diagnostics positions Lucence to offer advanced liquid biopsy solutions to cancer centers seeking cutting-edge precision health tools.

Funding and credibility Over US$80 million in funding and active participation in high-profile conferences and collaborations enhance credibility for negotiating large-scale deployments with healthcare networks and payers.

Preventive care demand Growing demand for preventive healthcare and early cancer detection aligns with Lucence’s liquid biopsy offerings, presenting opportunities with hospitals, health systems, and employer-based screening programs.